Trogenix Appoints Industry Veterans to Strengthen Board
News related to:Trogenix Ltd · 3 min read
Edinburgh, UK, 10 November 2026, Trogenix, a clinical-stage precision oncology company developing a new generation of programmable medicines, has appointed industry veterans John Young as Chair of the Board and Josh Murray as Non-Executive Director to support its global strategy, commercial foundation, and patient access.
John Young brings more than 35 years of operational and commercial leadership experience, having served as Group President and Chief Business Officer at Pfizer from 2019 to 2022. During his tenure, Young led business development, corporate strategy, portfolio and decision analysis, and patient access across the company's global operations. He also played a pivotal role in Pfizer’s COVID-19 response, leading the company’s COVID SWAT team that oversaw the development of the Pfizer-BioNtech COVID-19 vaccine and Pfizer’s COVID-19 anti-viral program.
Prior to his role at Pfizer, Young was Group President of Pfizer Innovative Health, overseeing six global business units including Oncology, Inflammation & Immunology, Internal Medicine, Rare Disease, Vaccines, and Consumer Healthcare. Following his retirement from Pfizer, Young joined the board of Novartis as a non-executive director and has also served on the boards of several innovative biotechnology companies.
Josh Murray, a biotechnology executive with deep expertise in strategy and capital markets, currently serves as Chief Financial Officer and Head of Strategy at Orca Bio. At Goldman Sachs, Murray spent 15 years, most recently as Managing Director and Head of West Coast Healthcare Capital Markets, advising many of the world's leading biotechnology and life sciences companies on financing, strategic growth initiatives, and corporate transactions. He also serves on the Board of Nasdaq-listed Corcept Therapeutics.
The appointments come at a pivotal time for Trogenix, which has seen significant momentum in recent months. In April 2026, the company published breakthrough pre-clinical data in Nature, and in May 2026, the first patient was dosed in the Company’s Phase I/II ADePT trial for glioblastoma. The ADePT (AAV Mediated Dual-Payload Gene Therapy) trial is an open-label clinical trial of TGX-007 in approximately 65 patients with newly diagnosed and recurrent glioblastoma. Eligible patients will receive a single intratumoral injection of TGX-007 followed by the pro-drug valaciclovir orally for up to 21 days before proceeding to standard-of-care surgery.
Glioblastoma, the most common and aggressive primary brain tumour in adults, affects approximately 200,000 people globally every year. Despite decades of research, standard-of-care treatments still leave newly diagnosed glioblastoma patients with a median overall survival of approximately 15 months, decreasing to approximately 6 months in recurrent patients.
The Company launched in 2023 based on co-founder Professor Steve Pollard’s groundbreaking research at the University of Edinburgh, including its UK Centre for Mammalian Synthetic Biology and Institute for Regeneration and Repair, and the Cancer Research UK Scotland Centre. In October 2025, Trogenix completed a £70m/$95m Series A financing led by IQ Capital, with investment from its existing investors and new investors Eli Lilly & Co., Meltwind, LongeVC, and Calculus Capital. The funding is enabling the rapid advancement of Trogenix’s robust pipeline of potentially curative cancer therapies across multiple aggressive solid tumours into the clinic.
Dima Kuzmin, Co-founder of Trogenix and Managing Partner at 4BIO Capital, will step down as Chair, a role he has held since the company’s founding in 2023. Kuzmin has been instrumental in the creation and development of Trogenix, working closely with the Company from its earliest days, supporting its financing and growth through key milestones, and helping establish the foundations for its transition into a clinical-stage oncology company. He will remain on the Board as a Director and continue to play an active role in supporting the Company's strategy, growth, and long-term vision.